华特达因(000915) - 2018 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2018 was ¥456,490,788.31, representing a 1.82% increase compared to ¥448,311,308.58 in the same period last year[5]. - The net profit attributable to shareholders decreased by 14.56% to ¥73,931,901.38 from ¥86,531,123.69 year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses also fell by 14.84% to ¥73,569,011.25[5]. - Basic and diluted earnings per share decreased by 13.51% to ¥0.32 from ¥0.37[5]. - The weighted average return on equity declined by 1.73 percentage points to 4.79% from 6.52%[5]. Cash Flow and Assets - The net cash flow from operating activities surged by 974.35% to ¥90,939,989.43, compared to ¥8,464,653.19 in the previous year[5]. - Total assets increased by 2.52% to ¥2,844,830,963.72 from ¥2,775,008,183.76 at the end of the previous year[5]. - As of March 31, 2018, the company's prepayments increased by 44.64% to ¥62,781,859 compared to ¥43,406,255.65 at the end of 2017, primarily due to increased marketing expenses by its subsidiary Shandong Dain Ocean Biological Pharmaceutical Co., Ltd.[14]. - Other current assets rose by 72.13% to ¥2,993,396.14, attributed to an increase in unrecoverable input tax and accrued repair costs[14]. - The company's construction in progress increased by 34.26% to ¥163,431,439.99, mainly due to payments made for construction by its subsidiary[14]. Expenses and Financial Management - Sales expenses surged by 72.40% to ¥132,577,654.52, driven by higher marketing costs incurred by its subsidiary[14]. - The company reported a 125.12% rise in financial expenses to ¥1,301,631.11, primarily due to increased cash discounts by its subsidiary[14]. - The company's long-term deferred expenses increased by 30.58% to ¥17,377,443.61, mainly due to office renovation costs incurred by its subsidiary[14]. - The company’s cash paid for investments decreased by 58.51% to ¥66,408,420.54, attributed to reduced purchases of bank wealth management products by its subsidiary[15]. - The company’s cash paid for debt repayment decreased by 47.50% to ¥21,000,000, reflecting a reduction in bank loan repayments[15]. Shareholder Information - The company reported a total of 26,520 common shareholders at the end of the reporting period[10]. - The largest shareholder, Shandong University Industry Group Co., Ltd., holds 20.72% of the shares, amounting to 48,544,340 shares[10]. - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[11]. Other Developments - The company is in the process of transferring property ownership for the purchased "Beijing Dain High-Tech Children's Drug Research Institute Co., Ltd."[16].